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A B S T R A C T
Background: Epstein-Barr virus (EBV) is closely associated with the high incidence of nasopharyngeal carcinoma
in worldwide. Vaccination is one strategy with the potential to prevent the occurrence of EBV-associated cancers,
but a suitable vaccine is yet to be licensed. Much vaccine development research focuses on the GP350/220
protein of EBV as it contains an immunogenic epitope at residues 147–165, which efficiently stimulates IgG
production in vitro. We examined the ability of this epitope (EBVepitope) to induce IgG production in mice.
Methods: The antibody binding pattern of the epitope was analyzed using bioinformatics tools. The IgG pro-
duction in mice were examined by FACS Calibur™ Flow cytometer.
Results: The epitope bound the 72A1 monoclonal antibody at the same site as GP350/220 protein, indicating
that the epitope should stimulate B cells to produce antibody. Moreover, in vivo administration of EBVepitope
successfully induced IgG expression from B cells, compared with controls. Further investigation indicated that
the relative number of B cells expressing IgE in EBVepitope-treated mice was lower than controls.
Conclusions: Our data suggest that this EBV GP350 epitope is able to induce IgG expression in vivo without
causing allergic reactions, and represents a potential EBV vaccine candidate.
1. Background
Epstein-Barr Virus (EBV) has been implicated in the development of
various malignancies [1] such as nasopharyngeal carcinoma (NPC)
[2,3] lymphoepithelioma [4], gastric carcinoma [5], and progression of
cervical cancer [6]. This virus is strongly associated with the high in-
cidence of NPC in the worldwide [7] and therefore, preventative ther-
apeutics are urgently needed. Vaccination is one way to prevent EBV
infection or EBV caused-disease. The vaccine also could be used as
therapeutic agent to prevent EBV spread from cell-to-cell within a host
and thus reduce the incidence of EBV-driven cancers. However, the
vaccine of the EBV has not been licensed.
Identification of an antigenic viral protein that binds to a host re-
ceptor is an important goal in EBV vaccine development. GP350/220
protein of EBV is known to bind to CD21/CR2 on the host cell surface,
facilitating the virus infection [8]. Monoclonal antibodies (mAbs)
against this protein have been shown to neutralize the EBV [8]. Ad-
ministration of mAbs against the GP350/220 protein have also been
shown to prevent the development of EBV-positive tumors in animal
models [9]. Therefore, this epitope shows promise as a candidate EBV
vaccine against NPC.
In our previous study, we found that GP350/220 protein contains an
epitope that can stimulate in vitro antibody production [10]. The epi-
tope between amino acid residues 147–165 of GP350/220 protein are
conserved in several EBV strains [11]. Thus, epitope-based vaccine
development using this epitope is very promising, with the potential to
be effective across multiple strains of EBV. Herein, we modeled the
epitope structure, its binding activity to monoclonal antibody against
EBV, 72A1 mAb, and also tested the ability of candidate vaccine epitope
to stimulate IgG production in experimental animals.
2. Methods
2.1. Modeling the tertiary structure of peptides and proteins
The epitope peptide of EBV was identified previously [11], and
designated EBVepitope for the purposes of this study. The tertiary (3D)
structure of EBVepitope was then modeled using the PEPstrMOD server
[12]. Meanwhile, the antibody structure was also modeled according to
the mAb 72A1 heavy- and light-chain variable region sequences [13] by
using the antibody variable region of homology modeling server, Ro-
settaAntibody [14]. The results of modeling were then visualized with
Discovery Studio, BIOVIA [15].
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2.2. Protein interaction analysis
The binding pattern of EBVepitope with the 72A1 mAb was done
using the PatchDock server [16]. Binding patterns of the antibody-
epitope complex were then compared with the binding pattern of
GP350/220 to the mAb. The 3D structure of the GP350/220 protein
was taken from the Protein Data Bank with accession code 2H6O [17].
The interaction of peptide amino acids with the antibody was analyzed
by LigPlot + program [18] and tabulated (Fig. 2A).
2.3. Peptide preparation and animal treatment
EBVepitope [9] was synthesized by Genescript and then used as an
antigen to induce antibody production in BALB/c mice. In this study,
we used twelve 3-week-old male mice with body weight± 10 g, di-
vided into four groups. Each group of mice was subcutaneously injected
with 50 μg of peptide (∼22 μL) mixed with 200 μL of adjuvant (pept
+), 50 μg (∼22 μL) peptide (pept), 40 μg (∼20 μL) lipopolysaccharide
(LPS) and ∼20 μL phosphate buffered saline (PBS) as a control group.
Two injections were given, with the second injection being given on day
7 as a booster. Complete Freund's Adjuvant was used for the first in-
jection, followed by Incomplete Freund's Adjuvant in the booster in-
oculation on day 7. The experimental animals were maintained in cages
with unrestricted access to food and water.
2.4. Lymphocyte cell isolation and immunostaining
The treated mice were sacrificed by neck dislocation; spleens were
then collected and washed with 1mL of sterile PBS. Next, spleens were
crushed with the base of a syringe, filtered through sterile gauze and the
homogenates were suspended in 5mL of PBS. The suspension was
centrifuged at 2500 rpm at 4 °C for 5min. The supernatant was then
discarded, and the pellet was resuspended in 1mL of PBS. Fifty mi-
croliters of the suspension was taken and put in a 1.5-mL sterile mi-
crotube containing 300 μL of PBS. The microtube was centrifuged at
2500 rpm at 4 °C for 5min. The supernatant was then removed, and the
pellet was resuspended in the residual PBS and immunostained for flow
cytometric analysis. Forty microliters of fluorescein isothiocyanate
(FITC)-conjugated anti-mouse B220 (clone: RA3-6A2; BioLegend, San
Diego, CA), PE-conjugated anti-mouse IgE (clone: RME-1; BioLegend)
and PE-Cy7-conjugated anti-mouse IgG (clone: Poly 4053; Biolegend)
was added to each sample.
2.5. Cell counting and data analysis
The stained cells were diluted in 400 μL of PBS and put in a flow
cytometer cuvette for analysis on a FACSCalibur™ flow cytometer (BD
Biosciences, San Jose, CA) to calculate the relative numbers of B cells
expressing IgG and IgE. The data were analyzed by the normality test
and homogeneity test of variance, followed by a one-way ANOVA.
3. Results
The modeling analysis of EBVepitope showed that the epitope
structure had a coil shape and was therefore very similar to its native
structure in the intact protein, GP350/220 (Fig. 1A). This structure of
EBVpeptide is stable as it is formed by many hydrogen bonds (Fig. 1B).
Due to the stability of the EBVepitope structure, it successfully bound to
Fig. 1. The tertiary structure of EBVepitope (A) showed a coil structure with many hydrogen donors/acceptors (B). The epitope could bind 72A1 mAb in both the
heavy- (purple) and light-chain (cyan) regions (C), which was similar to the binding pattern between the intact GP350/220 protein and 72A1 mAb (D). (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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the anti-GP350/220 mAb, 72A1. The peptide could bind in both the
heavy- and light-chain variable regions of the 72A1 mAb. We then
compared this with the binding pattern of the 72A1 mAb with EBVe-
pitope and GP350/220. The results of this analysis indicated that EB-
Vepitope and GP350/220 bound 72A1 at the similar site. The similarity
in binding pattern between the peptide and the intact protein indicates
that the peptide should be able to stimulate B cells to produce anti-
bodies in a manner similar to the whole protein.
To further elucidate the molecular interaction between the 72A1
mAb and EBVepitope, we used LigPlot + software. The analysis results
of these interactions indicated that the majority of peptides interacted
with the heavy chain rather than the light chain of the variable region
of 72A1 mAb (Fig. 2A and B). Analysis of multiple interactions showed
that the bonds between molecules were vigorous and stable, illustrating
that EBVepitope can bind the antibody in a stable manner, so it is likely
that the peptide is able to bind the native cell-bound receptor and sti-
mulate B cells to produce antibodies.
We next tested the ability of EBVepitope in inducing the production
of antibodies in vivo using a mouse model. Our results indicated that the
peptide was able to induce the production of IgG in mice. The number
of B cells (B220+ cells) that expressed IgG increased in mice injected
with either peptide alone (38.08%) or peptide plus adjuvant (pept+;
34.81%), compared with the control (30.34%) (Fig. 2C). Injection of
LPS also successfully induced IgG production (39.4%).
4. Discussion
Our data confirmed that administration of this specific peptide se-
quence was able to increase the production of IgG antibodies in mice,
compared with controls. Moreover, EBVepitope alone was capable of
inducing IgG expression better than EBVepitope plus adjuvant. This
may be a result of an imbalance in the ratio of EBVepitope to adjuvant
in the injected suspension. Too much adjuvant could result in depot
effects, or the antigen could be swamped by the adjuvant [19] or by
serum IgM. This would make it difficult for B cells to directly access the
peptide, thus limiting the induction of IgG.
Vaccination can induce CD203c expression in basophils, which may
stimulate IgE production [20]. Such an increase in IgE levels is un-
desirable and should be avoided to prevent potential vaccination side
effects. However, we found that the relative number of B cells expres-
sing IgE in EBVepitope-treated mice was lower than that observed in
controls (Fig. 2D). Furthermore, the relative numbers of IgE-expressing
B cells in the pept + group was higher compared with the control.
These data indicate that administration of adjuvant increased the risk of
allergic reaction following vaccination, as the adjuvant likely contained
a substance that was able to increase IgE production [21].
Based on the data suggesting the epitope has potential for devel-
oping the vaccine candidate for control proliferation of EBV. Vaccine is
one of important step to prevent infection of EBV and also cancer epi-
demiology, since the EBV infected 90% of world population [22] and
linked to the multiple cancers. Even the prevalence might related to the
socio-economic of the population. In most cases, EBV-infected individu
has no symptom, but if the virus-host balance is disturbed, could be
associated with several lymphomas. In Argentina, EBV infection is
mostly subclinical and have seropositive by 3 years old [23]. Ser-
oprevalence of EBV also increase in US ranging from 54.1% for 6–8 year
olds and 82.9% for 18–19 year olds in 2010 [24]. Therefore, vaccina-
tion for the childhood is very important to prevent the EBV caused
diseases. However, even though several vaccine candidate has been
examine in the clinical trial but none is licensed [25].
5. Conclusion
Our chosen epitope on the GP350/220 protein of EBV has a stable
coil structure, which is very similar to its native structure in the intact
protein. Therefore, this epitope remains able to recognize the 72A1
Fig. 2. The EBVpeptide interacted with 72A1 mAb in both
the heavy and light chains (A and B), and was able to induce
IgG production in B cells compared with the control (C).
Administration of EBVepitope alone was sufficient to stimu-
late IgG without triggering IgE production (D). Error bar of
Histogram indicated Standard deviation of within the group.
The ANOVA test suggested that among group of the treatment
was significantly different; with P value is 0.0168 for IgG
expressed B cell population, and P value is 0.0022 for IgE
expressed B cell population. *indicated by the amino acid
forming the hydrogen bond; Pept+, EBVepitope mixed with
Adjuvant; Pept, EBVepitope alone; LPS, lipopolysaccharide.
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mAb against GP350/220 protein. Furthermore, this stability of struc-
ture retains the immunogenicity of the epitope in vivo, facilitating the
induction of IgG in mice. In the absence of adjuvant, IgG is increased,
while undesirable IgE remains low. Our findings suggest that this
peptide has the potential to be developed as a safe vaccine without
causing allergic reactions.
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